Isolation: Isolation to a limited extent till these patients is treated for a minimum period of three to six months is necessary. Vaccine for immunoprophylaxis is IMMLEP programme. A future vaccine should have high efficacy. Chemotherapy: Paucibacillary cases (TT, BT, I), Cap rifampicin (600 mg) once a month. Tablet DDS 100 mg daily. Multibacillary cases (BL.LL): Cap rifampicin 600 mg daily for 14 days and thereafter once a month for 24 months. Cap clofazimine 100 mg on alternate days. Tab DDS 100 mg daily for 24 months. Management of reaction in leprosy. Type I Reaction: Seen in BT and BL leprosy which is medicated through a change in cell-mediated immunity. (i) Prednisolone 1 mg, (ii) Non-steroidal analgesics like aspirin, (iii) Chloroquine 150 mg BD, (iv) Clofazimine 100 mg 3 times a day, and (v) Limited decompression of the entrapped nerves. Type II reaction (ENL reaction): Characterized by appearance of sudden crops of erythematous tender maculopapular, nodular lesions. The Type II reaction is generally managed as under: (i) Clofazimine dose is increased to 100 mg TDS. (ii) Non-steroidal analgesics in adequate doses. (iii) Corticosteroids in doses of 40 mg per day. (iv) Thalidomide (100 mg) TDS is also helpful. Management of deformities: Most of these primary and secondary deformities can be prevented by a timely diagnosis, treatment of leprosy patients and detected of type I and type II reactions and their proper management. Physiotherapy: It plays a great role in the management of leprosy patients with or without deformities.